CJ-30060

CJ-30060 is an investigational small molecule drug being evaluated primarily for the treatment of solid tumors, with a focus on aggressive cancers that have limited therapeutic options. It acts as a multi-targeted agent, functioning as a calcium channel blocker, angiotensin II receptor blocker (ARB), and HMG-CoA reductase inhibitor. The drug has been studied in clinical trials to assess its pharmacokinetics and safety compared to established therapies such as Exforge (amlodipine/valsartan) and Crestor (rosuvastatin). Its development suggests potential utility in oncology due to its combined mechanisms of action targeting multiple pathways relevant to tumor growth and survival[1][2][3][4].